Feedback / Questions
E-602 - Palleon Pharma
https://www.businesswire.com/news/home/20250402600282/en/Palleon-Pharmaceuticals-Announces-NMPA-IND-Clearance-to-Proceed-with-Phase-2-Clinical-Trial-of-E-602-HLX79-a-First-In-Class-Treatment-for-Autoimmune-Diseases
Apr 2, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next